Cargando…
Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer‐related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase transloca...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507646/ https://www.ncbi.nlm.nih.gov/pubmed/28487464 http://dx.doi.org/10.1634/theoncologist.2016-0458 |
_version_ | 1783249767376093184 |
---|---|
author | Baik, Christina S. Myall, Nathaniel J. Wakelee, Heather A. |
author_facet | Baik, Christina S. Myall, Nathaniel J. Wakelee, Heather A. |
author_sort | Baik, Christina S. |
collection | PubMed |
description | Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer‐related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocation, has led to the development of novel therapies that directly target mutant proteins and associated signaling pathways, resulting in improved clinical outcomes. As sequencing techniques have improved, the molecular heterogeneity of NSCLC has become apparent, leading to the identification of a number of potentially actionable oncogenic driver mutations. Of these, one of the most promising therapeutic targets is B‐Raf proto‐oncogene, serine/threonine kinase (BRAF). Mutations in BRAF, observed in 2%–4% of NSCLCs, typically lead to constitutive activation of the protein and, as a consequence, lead to activation of the mitogen‐activated protein kinase signaling pathway. Direct inhibition of mutant BRAF and/or the downstream mitogen‐activated protein kinase kinase (MEK) has led to prolonged survival in patients with BRAF‐mutant metastatic melanoma. This comprehensive review will discuss the clinical characteristics and prognostic implications of BRAF‐mutant NSCLC, the clinical development of BRAF and MEK inhibitors from melanoma to NSCLC, and practical considerations for clinicians involving BRAF mutation screening and the choice of targeted therapy. IMPLICATIONS FOR PRACTICE. Personalized medicine has begun to provide substantial benefit to patients with oncogene‐driven non‐small cell lung cancer (NSCLC). However, treatment options for patients with oncogenic driver mutations lacking targeted treatment strategies remain limited. Direct inhibition of mutant B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and/or downstream mitogen‐activated protein kinase kinase (MEK) has the potential to change the course of the disease for patients with BRAF‐mutant NSCLC, as it has in BRAF‐mutant melanoma. Optimization of screening strategies for rare mutations and the choice of appropriate agents on an individual basis will be key to providing timely and successful intervention. |
format | Online Article Text |
id | pubmed-5507646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | AlphaMed Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-55076462018-07-01 Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy Baik, Christina S. Myall, Nathaniel J. Wakelee, Heather A. Oncologist Academia‐Pharma Intersect: Lung Cancer Non‐small cell lung cancer (NSCLC) remains the leading cause of cancer‐related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocation, has led to the development of novel therapies that directly target mutant proteins and associated signaling pathways, resulting in improved clinical outcomes. As sequencing techniques have improved, the molecular heterogeneity of NSCLC has become apparent, leading to the identification of a number of potentially actionable oncogenic driver mutations. Of these, one of the most promising therapeutic targets is B‐Raf proto‐oncogene, serine/threonine kinase (BRAF). Mutations in BRAF, observed in 2%–4% of NSCLCs, typically lead to constitutive activation of the protein and, as a consequence, lead to activation of the mitogen‐activated protein kinase signaling pathway. Direct inhibition of mutant BRAF and/or the downstream mitogen‐activated protein kinase kinase (MEK) has led to prolonged survival in patients with BRAF‐mutant metastatic melanoma. This comprehensive review will discuss the clinical characteristics and prognostic implications of BRAF‐mutant NSCLC, the clinical development of BRAF and MEK inhibitors from melanoma to NSCLC, and practical considerations for clinicians involving BRAF mutation screening and the choice of targeted therapy. IMPLICATIONS FOR PRACTICE. Personalized medicine has begun to provide substantial benefit to patients with oncogene‐driven non‐small cell lung cancer (NSCLC). However, treatment options for patients with oncogenic driver mutations lacking targeted treatment strategies remain limited. Direct inhibition of mutant B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and/or downstream mitogen‐activated protein kinase kinase (MEK) has the potential to change the course of the disease for patients with BRAF‐mutant NSCLC, as it has in BRAF‐mutant melanoma. Optimization of screening strategies for rare mutations and the choice of appropriate agents on an individual basis will be key to providing timely and successful intervention. AlphaMed Press 2017-05-09 2017-07 /pmc/articles/PMC5507646/ /pubmed/28487464 http://dx.doi.org/10.1634/theoncologist.2016-0458 Text en © 2017 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Academia‐Pharma Intersect: Lung Cancer Baik, Christina S. Myall, Nathaniel J. Wakelee, Heather A. Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title | Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title_full | Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title_fullStr | Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title_full_unstemmed | Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title_short | Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy |
title_sort | targeting braf‐mutant non‐small cell lung cancer: from molecular profiling to rationally designed therapy |
topic | Academia‐Pharma Intersect: Lung Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507646/ https://www.ncbi.nlm.nih.gov/pubmed/28487464 http://dx.doi.org/10.1634/theoncologist.2016-0458 |
work_keys_str_mv | AT baikchristinas targetingbrafmutantnonsmallcelllungcancerfrommolecularprofilingtorationallydesignedtherapy AT myallnathanielj targetingbrafmutantnonsmallcelllungcancerfrommolecularprofilingtorationallydesignedtherapy AT wakeleeheathera targetingbrafmutantnonsmallcelllungcancerfrommolecularprofilingtorationallydesignedtherapy |